- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
NeuroLogica Gets FDA Nod for New Mobile CT Scanner
Enhancements for the BodyTom 64 Point-of-Care Mobile Computed Tomography (CT) Scanner include upgraded cross-sectional imaging capabilities and a Linux operating system.
The Food and Drug Administration (FDA) has granted 510(k) clearance for the BodyTom® 64 Point-of-Care Mobile Computed Tomography Scanner, according to NeuroLogica, the manufacturer of the device and subsidiary of Samsung Electronics.
Incorporating clinician feedback in regard to the BodyTom Elite CT system, NeuroLogica doubled the capability of the BodyTom 64 system to generate upward of 64 cross-sectional images of a patient’s body and added a Linux operating system.
The device can reportedly be utilized in a variety of settings. For interventional radiologists, NeuroLogica said the BodyTom 64 provides multi-slice CT capabilities and facilitates easy rescans for stages of needle guidance. The BodyTom 64 device can provide neuroimaging guidance for extracranial procedures and is well-suited to trauma and emergency room settings with a unique combination of battery operation and internal lead shielding, added NeuroLogica.
“We’re thrilled to build off our expertise and elevate point-of-care imaging with our BodyTom64, which can transform any room in a hospital into an advanced imaging suite,” noted Jason Koshnitsky, senior director of Global Sales and Marketing at NeuroLogica.
CT Study Reveals Key Indicators for Angiolymphatic Invasion in Non-Small Cell Lung Cancer
January 15th 2025In computed tomography (CT) scans for patients with solid non-small cell lung cancer (NSCLC) < 30 mm, emerging research suggests the lollipop sign is associated with a greater than fourfold likelihood of angiolymphatic invasion.
New CT and MRI Research Shows Link Between LR-M Lesions and Rapid Progression of Early-Stage HCC
January 2nd 2025Seventy percent of LR-M hepatocellular carcinoma (HCC) cases were associated with rapid growth in comparison to 12.5 percent of LR-4 HCCs and 28.5 percent of LR-4 HCCs, according to a new study.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Can AI Facilitate Single-Phase CT Acquisition for COPD Diagnosis and Staging?
December 12th 2024The authors of a new study found that deep learning assessment of single-phase CT scans provides comparable within-one stage accuracies to multiphase CT for detecting and staging chronic obstructive pulmonary disease (COPD).
Study Shows Merits of CTA-Derived Quantitative Flow Ratio in Predicting MACE
December 11th 2024For patients with suspected or known coronary artery disease (CAD) without percutaneous coronary intervention (PCI), researchers found that those with a normal CTA-derived quantitative flow ratio (CT-QFR) had a 22 percent higher MACE-free survival rate.
